HIV Infections Clinical Trial
Official title:
A Phase II Open Randomized Comparison of 566C80 and Pentamidine Isethionate for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients Who Are Intolerant of Trimethoprim / Sulfamethoxazole
NCT number | NCT00001996 |
Other study ID # | 053B |
Secondary ID | 05 |
Status | Completed |
Phase | Phase 2 |
First received | November 2, 1999 |
Last updated | June 23, 2005 |
To compare the safety of atovaquone (566C80) with intravenous (IV) pentamidine for the treatment of mild to moderate Pneumocystis carinii pneumonia (PCP) in AIDS patients who are intolerant of therapy with trimethoprim / sulfamethoxazole (TMP / SMX) by comparing the incidence of premature discontinuation of therapy due to toxicity. To compare the efficacy of 566C80 with intravenous (IV) pentamidine for the treatment of mild to moderate PCP in the same population.
Status | Completed |
Enrollment | 0 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 13 Years and older |
Eligibility |
Inclusion Criteria Patients must have the following: - History of, or are currently experiencing, intolerance to TMP / SMX, or to another sulfonamide, which required discontinuation of therapy. - Pneumocystis carinii pneumonia (PCP). - Willing and able to give informed consent. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded. - Malabsorption disorder or vomiting that would, in the judgement of the investigator, potentially limit the retention and absorption of an oral therapy. - Concurrent bacterial, fungal, or viral pneumonitis, pulmonary Kaposi's sarcoma, or other concurrent illness, or chronic pulmonary disease that, in the investigator's opinion, would make interpretation of drug efficacy difficult. - Present occurrences of abnormal prolongation of QT interval on standard, 12 lead EKG. Concurrent Medication: Excluded: - Drugs with potential anti-pneumocystis effect (eg: - sulfonamides, dapsone, trimethoprim, other dihydrofolate reductase (DHFR) inhibitors, primaquine, clindamycin, sulfonylureas). - Ganciclovir. - Zidovudine. - Investigational agents including anti-retroviral agents (ddI, ddC, etc.). Patients receiving these drugs prior to entry must discontinue their use during the therapy phase (21 days) of the trial. - Corticosteroids (except replacement therapy) during the 21 day treatment period (Strata A and C Patients). - Class 1A antiarrhythmics (ie: - quinidine, procainamide, disopyramide). Patients with the following are excluded: - Judged by the investigator to be in impending respiratory failure. - Known intolerance to parenteral pentamidine isethionate, or therapeutic failure with same for treatment of current episode of PCP. - Significant psychosis or emotional disorder that, in the investigator's opinion, would preclude the patient from adhering to the protocol. - Inability or unwillingness to take medication orally or with food. - Prior documented glucose-6-phosphate dehydrogenase (G6PD) deficiency. - History, or present occurrences, of abnormal prolongation of QT interval on standard, 12 lead EKG. - Termination from FDA 053A due to toxicity. - For patients entering under historic intolerance criteria (Groups A and B), prior therapy for this episode of PCP is an exclusion. Prior Medication: Excluded: - Treatment within 4 weeks of entry for a prior episode of PCP. - For patients entering under historic intolerance criteria (Groups A and B), prior therapy for this episode of PCP is an exclusion. Required: - Adjuvant prednisone for patient enrolled in Strata B or D. |
Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Infectious Disease Research Consortium of Georgia | Atlanta | Georgia |
United States | East Bay AIDS Ctr | Berkeley | California |
United States | Boston City Hosp | Boston | Massachusetts |
United States | Massachusetts Gen Hosp | Boston | Massachusetts |
United States | Univ of Cincinnati | Cincinnati | Ohio |
United States | Kaiser Foundation Hosp | Harbor City | California |
United States | Baylor College of Medicine | Houston | Texas |
United States | Gathe, Joseph, M.D. | Houston | Texas |
United States | Cedars Sinai Med Ctr | Los Angeles | California |
United States | UCLA CARE Ctr | Los Angeles | California |
United States | Regional Med Ctr at Memphis | Memphis | Tennessee |
United States | Beth Israel Med Ctr | New York | New York |
United States | Harlem AIDS Treatment Group / Harlem Hosp Ctr | New York | New York |
United States | Saint Vincent's Hosp and Med Ctr | New York | New York |
United States | UCI Med Ctr | Orange | California |
United States | Buckley Braffman Stern Med Associates | Philadelphia | Pennsylvania |
United States | Portland Veterans Adm Med Ctr / Rsch & Education Grp | Portland | Oregon |
United States | AIDS Community Research Consortium | Redwood City | California |
United States | Davies Med Ctr | San Francisco | California |
United States | Dr Patrick Joseph | San Ramone | California |
Lead Sponsor | Collaborator |
---|---|
Glaxo Wellcome |
United States,
Dohn M, Weinberg W, Rosenstock J, Follansbee S, Torres R, Caldwell P. Atovaquone vs. pentamidine for pneumocystis carinii pneumonia in patients with AIDS. Int Conf AIDS. 1993 Jun 6-11;9(1):372 (abstract no PO-B10-1421)
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |